Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
← catalyst calendarSponsored by RedHill Biopharma Limited (industry) · RDHL — their whole pipeline →.
Phase
Phase 2
Status
Unknown status
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
142estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2024 | estimated | When the study began enrolling |
| Primary completion | Jun 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2019-07-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-01-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Traveler's Diarrhea
Interventions
- Drug: Rifamycin SV-MMX — also filed as Rifamycin
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFClinical Cure
measured 120 hours
Permalink · RDHL's whole pipeline · Catalyst calendar · Every registered study · What changed